Redesigned brain receptor drugs show promise for depression
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
Subscribe To Our Newsletter & Stay Updated